Sector ratings Altimmune, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-17 EDT			5-day change	1st Jan Change
2.870 ^USD	+0.70%		-5.90%	-20.50%

07-07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-29	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation
ALTIMMUNE, INC.	558M	-	B	-		-
ARGENX SE	53.83B		A
WUXI APPTEC CO., LTD.	52.1B		AAA
INSMED INCORPORATED	23.48B	-	A	-		-
BIONTECH SE	23.13B	-	-	-		-
WUXI BIOLOGICS (CAYMAN) INC.	19.36B		AAA
GENMAB A/S	17.56B		A
PHARMAESSENTIA CORPORATION	15.2B		AA
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	14.83B	-	AA	-		-
EXELIXIS, INC.	14.06B		BB
MADRIGAL PHARMACEUTICALS, INC.	12.76B	-	B	-		-
CYTOKINETICS, INCORPORATED	10.89B	-	AA	-		-
SUMMIT THERAPEUTICS INC.	10.72B	-	-	-		-
ARROWHEAD PHARMACEUTICALS, INC.	10.47B	-	BB	-		-
AKESO, INC.	10.38B		B
CRINETICS PHARMACEUTICALS, INC.	8.84B	-	BBB	-		-
SPYRE THERAPEUTICS, INC.	8.81B	-	BB	-	-	-
VAXCYTE, INC.	8.12B	-	BBB	-		-
REMEGEN CO., LTD.	8.07B		-
IMMUNITYBIO, INC.	8.04B	-	CCC	-		-
Average	16.56B		A
Weighted average by Cap.			A